Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Verizon Communications Inc (VZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Verizon Communications Inc — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Verizon Communications Inc trades at $44.67 (market cap $180.86B). The key difference: Verizon Communications Inc is far larger — about 37.1× Travere Therapeutics Inc. Common Stock's market cap, and Verizon Communications Inc pays a 6.5% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Verizon Communications Inc for 109 Days on average.
| TVTX | VZ | |
|---|---|---|
Market Cap | $4.88B | $180.86B |
Volume | 1,668,577 | 30,427,702 |
Sector | Health | Media |
52-Week High | $67.52 | $51.45 |
52-Week Low | $26.79 | $38.40 |
Typical Hold Time | 0 Days | 109 Days |
Enterprise Value | $5.01B | $367.56B |
Dividend Yield | — | 6.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Verizon (VZ) trades at $44.42, up 3.83% today, with a bearish technical signal but strong fundamentals including a P/E of 11.34 and a 15.63% ROE. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results due October 26, 2026. Recent news highlights its joint venture with AT&T and T-Mobile to expand satellite connectivity and a steady dividend of $0.71 payable November 2, 2026.
The outlook is mixed: low valuation and consistent cash flow support income appeal, but technical weakness and modest revenue growth pose near-term risks. Analyst consensus leans hold with a $47.83 price target, suggesting limited upside. Key risks include competitive pressures and high debt levels, though strong operational cash flow provides stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Verizon Communications Inc
Verizon Communications Inc. is an integrated telecommunications company that provides wire line voice and data services, wireless services, Internet services, and published directory information. The Company also provides network services for the federal government including business phone lines, data services, telecommunications equipment, and payphones.
Read more on VZ →
